<DOC>
	<DOC>NCT00908752</DOC>
	<brief_summary>The purpose of this study is to compare the Overall Survival (OS) of HCC patients who receive brivanib as adjuvant treatments to TACE therapy, with the OS of HCC patients who receive matched placebo with TACE therapy.</brief_summary>
	<brief_title>Phase III Trans-Arterial Chemo-Embolization (TACE) Adjuvant HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma, Hepatocellular</mesh_term>
	<criteria>For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Patients with diagnosis of hepatocellular carcinoma Cirrhotic status of ChildPugh Class A or B with a score of 7 ECOG performance status of 0 or 1 Adequate hematologic, hepatic, and renal function Exclusion criteria: Prior use of any systemic anticancer chemotherapy, immunotherapy, investigational or molecular targeted agents for HCC History of cardiac disease Active and untreated hepatitis B Inability to swallow tablets or untreated malabsorption syndrome History of human immunodeficiency virus (HIV) infection</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2016</verification_date>
	<keyword>HCC</keyword>
</DOC>